ASTH Financials Astrana Health, Inc.

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated 29 h ago Overview →

Growth & profitability

Revenue has grown 35.9% per year over the past 5 years.
Net income has grown slower than revenue (-8.6% vs 35.9% per year).
Operating margin has contracted, at 2.5% in the latest year.
Free cash flow has grown 18.4% per year over the past 5 years.

Financial health

Total debt ($1.0B) exceeds cash ($429M); net debt is $609M.
Total debt has grown in line with revenue (33.9% vs 35.9% per year).
Operating income covered interest expense 1.6× in the latest year.
Total debt is 8.4× EBITDA.

Shareholder returns

Dividends have been paid for 8 consecutive years, consuming 32.9% of earnings and 7.5% of free cash flow.
The dividend has declined 31.2% per year over the past 5 years.

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Free cash flow (CFO − capex)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key annual figures

FY	Revenue	Net income	Gross M	Op M	FCF	Total debt	Cash
2025	$3.2B	$24M	0.0%	2.5%	$104M	$1.0B	$429M
2024	$2.0B	$50M	0.0%	4.4%	$44M	$435M	$288M
2023	$1.4B	$58M	0.0%	6.1%	$40M	$278M	$294M
2022	$1.1B	$46M	0.0%	9.1%	$59M	$204M	$288M
2021	$774M	$46M	23.0%	12.7%	$51M	$184M	$233M
2020	$687M	$38M	21.5%	11.7%	$45M	$241M	$193M
2019	$561M	$14M	16.6%	5.8%	$13M	$232M	$103M
2018	$520M	$11M	30.5%	17.0%	$24M	$0	$107M
2017	$356M	$26M	23.3%	9.9%	$50M	—	$100M
2017	—	-$9M	—	—	—	—	$63M
2016	—	$11M	—	—	$19M	—	$55M
2016	—	-$9M	—	—	—	—	$9M
2015	—	-$2M	—	—	—	$11M	$5M
2014	—	-$5M	—	—	-$2M	—	$1M
2013	—	-$9M	—	—	$12157	—	$1M

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Free cash flow (CFO − capex, quarterly)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key quarterly figures

Quarter	Revenue	Net income	Gross M	Op M	FCF	Total debt	Cash
Mar '26	$965M	$14M	0.0%	3.0%	$64M	$1.0B	$478M
Dec '25	$951M	$6M	0.0%	1.9%	-$6M	$1.0B	$429M
Sep '25	$956M	$373000	0.0%	2.0%	$7M	$1.0B	$462M
Jun '25	$655M	$9M	0.0%	3.1%	$89M	$414M	$340M
Mar '25	$620M	$7M	0.0%	3.3%	$14M	$416M	$259M
Dec '24	$665M	-$7M	0.0%	0.1%	-$13M	$435M	$288M
Sep '24	$479M	$16M	0.0%	5.9%	$32M	$438M	$348M
Jun '24	$486M	$19M	0.0%	6.2%	$20M	$442M	$325M
Mar '24	$404M	$15M	0.0%	7.5%	$6M	$389M	$335M
Dec '23	$353M	$12M	0.0%	-1.1%	$12M	$278M	$294M
Sep '23	$348M	$22M	0.0%	11.2%	$11M	$209M	$274M
Jun '23	$348M	$13M	0.0%	7.8%	$14M	$208M	$294M
Mar '23	$337M	$13M	0.0%	6.6%	$2M	$206M	$275M
Dec '22	$294M	-$4M	0.0%	4.3%	$84M	$204M	$288M
Sep '22	$317M	$23M	0.0%	15.8%	-$39M	$202M	$184M
Jun '22	$270M	$12M	0.0%	5.7%	$8M	$201M	$234M
Mar '22	$263M	$14M	0.0%	10.0%	$7M	$185M	$238M
Dec '21	$195M	$12M	0.0%	1.2%	-$15M	$184M	$233M
Sep '21	$227M	$34M	0.0%	23.4%	$42M	$183M	$205M
Jun '21	$176M	$10M	0.0%	11.9%	$14M	$183M	$177M

Valuation over time

How the market has priced ASTH against its own fundamentals since 2024-02 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

The price-to-earnings ratio has risen from 43.3× (Feb '24) to 100.9× (Jun '26).
The price-to-sales ratio has fallen from 1.8× (Feb '24) to 0.8× (Jun '26).
The dividend yield has fallen from 2.5% (Feb '24) to 0.3% (Jun '26).

Price / earnings (P/E)

P/E

Price / sales (P/S)

P/S

Dividend yield (%)

Dividend yield %

Frequently asked questions

Is ASTH growing its revenue and profit?

Over the past 5 years, Astrana Health, Inc.'s revenue has grown 35.9% per year, and net income declined 8.6% per year. These are computed facts, not advice.

How much debt does ASTH have?

As of FY2025, Astrana Health, Inc. reported $1.0B of total debt against $429M of cash; operating income covered interest expense 1.6×.

What is ASTH's profit margin?

In FY2025, gross margin was —, operating margin 2.5%, and net margin 0.8%.

What is ASTH's P/E ratio?

As of Jun '26, Astrana Health, Inc. traded at a price-to-earnings ratio of about 100.9× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.